Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets.
{iframe}https://www.fiercebiotech.com/biotech/gilead-s-kite-pens-10-target-car-t-tech-deal-maxcyte{/iframe}